Synergism of hemopoietic growth factors on endothelial cell proliferation

Angiology

Volumn 48, Issue 2, 1997, Pages 141-147

  Sigoimas, George ^a   Steiner, Manfred ^a   Anagnostou, Athanasius ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 3;

ARTICLE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CHEMOTAXIS; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; UMBILICAL VEIN;

EID: 0031042326     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979704800207     Document Type: Article

References (38)

1. Folkman J, Klagsbrun M: Angiogenic factors. Science 235:442-447, 1987.
2. Kahaleh MB: The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol 10:51-56, 1992.
3. Hirschberg H, Bergh OJ, Thorsby E: Antigen presenting properties of human vascular endothelial cells. J Exp Med 152:249S-255S, 1980.
4. Favaloro EJ, Moraitis N, Bradstock K, et al: Co-expression of hemopoietic antigens on vascular endothelial cells: A detailed phenotypic analysis. Br J Hematol 74:385-394, 1990.
5. Fina L, Molgaard HV, Robertson D, et al: Expression of the CD34 gene in vascular endothelial cells. Blood 75:2417-2426, 1990.
6. Peault BM, Thiery JP, Le Douarin NM: Surface marker for hemopoietic and endothelial cell lineages in quail that is defined by a monoclonal antibody. Proc Natl Acad Sci USA 80:2976-2980, 1983.
7. Aye MT, Hashemi S, Leclair B, et al: Expression of stem cell factor and c-kit mRNA in cultured endothe- lial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF). Exp Hematol 20:523-527, 1993.
8. Boraschi D, Rambaldi A, Sica A, et al: Endothelial cells express the interleukin-1 receptor type I. Blood 78:1262-1267, 1991.
9. Hicks C, Cooley MA, Penny R: Investigation of interleukin 2 receptors on human endothelial cells. Growth Factors 5:201-208, 1991.
10. Bagby GC Jr, Dinarello CA, Wallace P, et al: Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest 78:1316-1323, 1986.
11. Fibbe WE, Daha MR, Hiemstra PS, et al: Interleukin 1 and Poly(rl):Poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. Exp Hematol 17:229-234, 1989.
12. Korpelainen El, Gamble JR, Smith WB, et al: The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor a and potentiates interleukin 8 secretion and neutrophil transmigration. Proc Natl Acad Sci USA 90:11137-11141, 1993.
13. Mantovani A, Dejana E: Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 10:370-375, 1989.
14. Podor TJ, Jirik FR, Loskutoff DJ, et al: Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann NY Acad Sci 557:374-377, 1989.
15. Bussolino F, Wang JM, Defilippi P, et al: Granulocyte-and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 337:471-473, 1989.
16. Brizzi MF, Garbarino G, Rossi PR, et al: Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells, J Clin Invest 91:2887-2892, 1993.
17. Anagnostou A, Lee ES, Kessimian N, et al: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87:5978-5982, 1990.
18. Van Hinsbergh VW, Mommaas-Kienhuis AM, Weinstein R, et al: Propagation and morphologic phenotypes of human umbilical cord artery endothelial cells. Eur J Cell Biol 42:101-110, 1989.
19. Shultz PJ, DiCorleto PE, Silver BJ, et al: Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255;F674-684, 1988.
20. Connolly DT, Stoddard BL, Harakas NK, et al: Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells. Biochem Biophys Res Commun 144:705-712, 1987.
21. Penn PE, Jiang DZ, Fei RG, et al: Dissecting the hematopoietic microenvironment. IX. Further characterization of murine bone marrow stromal cells. Blood 81:1205-1213, 1993.
22. Keating A, Singer JW, Killen PD, et al: Donor origin of the in vitro hematopoietic microenvironment after marrow transplantation in man. Nature 298:280-283, 1982.
23. Yanai N, Satoh T, Obinata M: Endothelial cells create a hematopoietic inductive microenvironment preferential to erythropoiesis in the mouse spleen. Cell Struct Funct 16:87-93, 1991.
24. Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. FASEB J 6:2591-2599, 1992.
25. Anagnostou A, Liu Z, Steiner M, et al: Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 91:3974-3978, 1994.
26. Yong K, Cohen H, Khwaja A, et al: Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood 77:1675-1680, 1991.
27. Colotta F, Bussolino F, Polentarutti N, et al: Differential expression of the common β and specific α chains of the receptors for GM-CSF, IL-3, and IL-5 in endothelial cells. Exp Cell Res 206:311-317, 1993.
28. Metcalf D: Implications of the polyfunctionality of hemopoietic regulators. Stem Cells 12:259-275, 1994.
29. Raine AEG: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1:97-100, 1988.
30. Eschbach JW: Erythropoietin-associated hypertension-reply. N Engl J Med 323:999-1000, 1990.
31. Baskin S, Lasker N: Erythropoietin-associated hypertension. N Engl J Med 323:999-1000, 1990.
32. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39:259-265, 1991.
33. Singbartl G: Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Invest 72(suppl 6):S36-S43, 1994.
34. Ballmer-Weber BK, Dummer R, Kung E, et al: Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 71:78-82, 1995.
35. Olthof CG, Baars JW, Wagstaff J, et al: Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements. Eur J Applied Phys Occup Phys 67:168-173, 1993.
36. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666-676, 1990.
37. de Vries EG, van Gameren MM, Willemse PH: Recombinant human interleukin 3 in clinical oncology. Stem Cells 11:72-80, 1993.
38. D'Hondt V, Guillaume T, Humblet Y, et al: Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: A pilot study. Bone Marrow Transplantation 13:261-264, 1994.